Inhibitors of APOL1 and methods of using same

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CAO, Jingrong, WANG, Tiansheng, LEDFORD, Brian, SENTER, Timothy J, MEDEK, Ales, DENIS, Francois, FORTIER, Anne, NICOLAS, Olivier, DORSCH, Warren A, HU, Kan-Nian, COME, Jon H, SAYEGH, Camil, GAGNON, Kevin, WITKOS, Faith, KRUEGER, Elaine B, HAMEL, Martine, NANTHAKUMAR, Suganthini S, SHI, Yi, DAKIN, Leslie A, BRODNEY, Michael, SHRESTHA, Muna, ROSE, Peter
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).